Perigon Wealth Management LLC Purchases 791 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Perigon Wealth Management LLC increased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 19.4% during the fourth quarter, HoldingsChannel reports. The fund owned 4,874 shares of the company’s stock after buying an additional 791 shares during the period. Perigon Wealth Management LLC’s holdings in Krystal Biotech were worth $605,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in KRYS. Vanguard Group Inc. increased its holdings in Krystal Biotech by 40.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after purchasing an additional 693,852 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Krystal Biotech by 1.0% in the first quarter. BlackRock Inc. now owns 1,716,095 shares of the company’s stock valued at $137,391,000 after purchasing an additional 16,499 shares in the last quarter. State Street Corp lifted its holdings in shares of Krystal Biotech by 52.3% in the first quarter. State Street Corp now owns 1,068,656 shares of the company’s stock valued at $71,108,000 after purchasing an additional 366,855 shares in the last quarter. First Light Asset Management LLC lifted its holdings in shares of Krystal Biotech by 5.6% in the first quarter. First Light Asset Management LLC now owns 717,936 shares of the company’s stock valued at $47,771,000 after purchasing an additional 37,766 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Krystal Biotech by 11.3% in the second quarter. Point72 Asset Management L.P. now owns 559,261 shares of the company’s stock valued at $65,657,000 after purchasing an additional 56,861 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Krystal Biotech news, CAO Kathryn Romano sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $130.00, for a total transaction of $325,000.00. Following the transaction, the chief accounting officer now owns 12,556 shares of the company’s stock, valued at $1,632,280. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Kathryn Romano sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $130.00, for a total value of $325,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,556 shares in the company, valued at approximately $1,632,280. The disclosure for this sale can be found here. Insiders have sold a total of 40,587 shares of company stock valued at $6,535,591 over the last 90 days. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

KRYS opened at $173.62 on Monday. Krystal Biotech, Inc. has a 52-week low of $82.09 and a 52-week high of $189.97. The firm has a market capitalization of $4.95 billion, a PE ratio of 2,170.52 and a beta of 0.85. The business’s 50-day simple moving average is $154.31 and its 200 day simple moving average is $128.46.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.82. The business had revenue of $42.14 million for the quarter, compared to analyst estimates of $27.43 million. During the same period last year, the firm earned ($1.25) EPS. On average, research analysts forecast that Krystal Biotech, Inc. will post 1.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

KRYS has been the topic of a number of research reports. William Blair restated an “outperform” rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Guggenheim boosted their price target on Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, Citigroup boosted their price target on Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $157.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).